Scheiner Zachary
Transaction: 06/15/2026
BUY
Change
+22,100
Price
$6.63
Filing
06/15/2026
Type
BUY
LENZ Therapeutics, Inc.
LENZ • Biotechnology
$3.27
— 0.00 (0.00%)
EarningsLatest report: Jun 30, 2026
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$102.59M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0Healthy liquidity · 13.8Negative growth trendWeak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 13, 2026, 12:18 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$3.27
Change0.00%
Shares Out31.37M
Market Cap$102.59M
Enterprise Value$-117.29M
52W Range4.68 - 50.40
Beta1.63
P/E-0.81
P/S4.78
P/B0.47
P/FCF-0.90
EV/Sales-5.46
Price$3.27
Change0.00%
Shares Out31.37M
Market Cap$102.59M
Enterprise Value$-117.29M
52W Range4.68 - 50.40
Beta1.63
P/E-0.81
P/S4.78
P/B0.47
P/FCF-0.90
EV/Sales-5.46
EV/EBITDA0.87
EV/FCF1.03
Earnings Yield-122.82%
FCF Yield-111.53%
Dividend Yield0.00%
Gross Margin96.31%
Oper. Margin-4.77%
Profit Margin-4.30%
Debt/Eq0.00
Current Ratio13.80
Quick Ratio13.80
Target$7.00
Target Upside114.07%
Target Median$7.00
Target Range7.00 - 7.00
Volume2.14M
Avg Volume869.39K
EPS Surprise-0.22
Investment DNA
How strong this company looks for long-term investors
35
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
55/100
Why this score▼
Manageable debt level · 0Healthy liquidity · 13.8Negative growth trendWeak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 5 analyst votes · 2026-10-19
90/100
Bullish
Bullish
4
Hold
1
Bearish
0
Price Target
2026-08-13
Low
$7.00
Mean
$7.00
Median
$7.00
High
$7.00
Insider Transactions
Recent executive and insider activity
Guerard Frederic
Transaction: 06/15/2026
BUY
Change
+22,100
Price
$6.63
Filing
06/15/2026
Type
BUY
Thunen Shelley B
Transaction: 06/15/2026
BUY
Change
+22,100
Price
$6.63
Filing
06/15/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Scheiner Zachary | BUY | +22,100 | $6.63 | 06/15/2026 | 06/15/2026 |
| Guerard Frederic | BUY | +22,100 | $6.63 | 06/15/2026 | 06/15/2026 |
| Thunen Shelley B | BUY | +22,100 | $6.63 | 06/15/2026 | 06/15/2026 |
| MCCOLLUM JAMES W | BUY | +22,100 | $6.63 | 06/15/2026 | 06/15/2026 |
| Drapkin Kimberlee C | BUY | +22,100 | $6.63 | 06/15/2026 | 06/15/2026 |
| George Jeffrey P. | BUY | +22,100 | $6.63 | 06/15/2026 | 06/15/2026 |
| RA CAPITAL MANAGEMENT, L.P. | BUY | +22,100 | $6.63 | 06/15/2026 | 06/15/2026 |
| Chevallard Daniel R. | BUY | +7,500 | $8.57 | 03/27/2026 | 03/30/2026 |
| Schimmelpennink Evert B. | BUY | +28,089 | $8.95 | 03/27/2026 | 03/30/2026 |
| George Jeffrey P. | BUY | +5,592 | $8.92 | 03/27/2026 | 03/30/2026 |
| Schimmelpennink Evert B. | BUY | +358,100 | $16.00 | 01/02/2026 | 01/06/2026 |
| Chevallard Daniel R. | BUY | +14,000 | Not reported | 01/02/2026 | 01/06/2026 |
| Chevallard Daniel R. | BUY | +84,200 | $16.00 | 01/02/2026 | 01/06/2026 |
| Odrich Marc | BUY | +14,000 | Not reported | 01/02/2026 | 01/06/2026 |
| Odrich Marc | BUY | +84,200 | $16.00 | 01/02/2026 | 01/06/2026 |
| Olsson Shawn | BUY | +14,000 | Not reported | 01/02/2026 | 01/06/2026 |
| Olsson Shawn | BUY | +84,200 | $16.00 | 01/02/2026 | 01/06/2026 |
| Olsson Shawn | SELL | -5,788 | $26.37 | 11/17/2025 | 11/19/2025 |
| Olsson Shawn | SELL | -10,000 | $2.08 | 11/17/2025 | 11/19/2025 |
| MCCOLLUM JAMES W | BUY | +10,500 | $22.79 | 11/07/2025 | 11/10/2025 |